Vertex is laying off 125 employees in Rhode Island and consolidating offices, following the discontinuation of a Type 1 ...

This was the stock's third consecutive day of gains.

The layoffs will be effective on Aug. 5, according to a letter sent to the state’s Department of Labor and Training.

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The company recently has expanded into another area ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach ...

Continue » This stock is Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech that's delivered a long track record of growth and profitability thanks to its leadership in the cystic fibrosis (CF ...

In addition to Bernstein, Vertex Pharmaceuticals also received a Hold from Erste Group’s Hans Engel in a report issued on May 23. However, on May 21, Bank of America Securities maintained a Buy ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 10.58% on an annualized basis producing an average annual return of 18.88%. Currently, Vertex Pharmaceuticals has ...

It will grow to $13.84 billion in 2029 at a compound annual growth rate (CAGR) of 16.7%.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, May 28, 2025 /EINPresswire.com/ -- The ...

Vertex Pharmaceuticals has authorized an additional share repurchase program of up to $4 billion. The program does not have an expiration date and can be discontinued at any time, the Boston-based ...